Extract

Single centre ,Phase IV , interventional, The study includes : 200 patients, 100 Patients will have Topical r-Hirudin (Thrombexx) and 100 patients will have placebo . The patients will be randomized to the active product (arm 1) or to placebo (arm 2). The study consists of 4 visits as the following : - Visit 1 : on day 1 to check patient eligibility and also for randomization . - Visit 2 : on day 4 to assess target parameters - Visit 3 : on day 8 to assess target parameters - Visit 4 : on day 16 to assess target parameters

Inclusion criteria

• r-Hirudin (Thrombexx) Efficacy in Treatment of Haematomas

Links

• ictrp
• nct